Philip Young

Prior to joining US Venture Partners, Phil Young was President & CEO of Oximetrix, a manufacturer of critical care instruments and disposables, where he spent 8 years growing the privately-held venture-backed company from $1 million in revenues to nearly $50 million. Prior to Oximetrix, Mr. Young spent 6 years at New Court Securities in venture capital and corporate finance, 2 years as a management consultant with McKinsey & Co., and 6 years on Admiral Rickover's project management staff at the Atomic Energy Commission.

Mr. Young has represented US Venture Partners on the boards of Aerogen, CardioThoracic Systems, CardioVascular Imaging Systems, CoCensys, Compugen, FemRx, Penederm, 3Dfx Interactive, Vical and Xoma--all of which became public companies. Currently Mr. Young sits on the boards of Zoran, a public company, as well as Aptus Endosystems, Bayhill Therapeutics, Caspian Networks, Claria, Dotomi, RelayHealth, Synarc, St. Francis Medical and Timi3 Systems.